End-of-day quote
Shanghai S.E.
03:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
25.69
CNY
|
+0.35%
|
|
+3.34%
|
-4.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
10,188
|
8,344
|
7,308
|
21,077
|
13,618
|
13,211
|
Enterprise Value (EV)
1 |
10,254
|
8,279
|
7,250
|
21,260
|
13,804
|
13,244
|
P/E ratio
|
27.2
x
|
65.2
x
|
213
x
|
-67.3
x
|
-34.3
x
|
150
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.29
x
|
6.86
x
|
6.59
x
|
24.7
x
|
13.7
x
|
10.3
x
|
EV / Revenue
|
6.33
x
|
6.8
x
|
6.54
x
|
24.9
x
|
13.9
x
|
10.3
x
|
EV / EBITDA
|
21.2
x
|
40.1
x
|
156
x
|
-65.5
x
|
-39
x
|
67.5
x
|
EV / FCF
|
-17.1
x
|
60
x
|
-7,048
x
|
-171
x
|
91.5
x
|
26.4
x
|
FCF Yield
|
-5.86%
|
1.67%
|
-0.01%
|
-0.58%
|
1.09%
|
3.79%
|
Price to Book
|
4.45
x
|
3.52
x
|
3.03
x
|
10
x
|
8
x
|
9.61
x
|
Nbr of stocks (in thousands)
|
4,94,031
|
4,92,000
|
4,89,491
|
4,89,491
|
4,89,491
|
4,89,491
|
Reference price
2 |
20.62
|
16.96
|
14.93
|
43.06
|
27.82
|
26.99
|
Announcement Date
|
25/03/19
|
29/04/20
|
28/04/21
|
29/04/22
|
21/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,619
|
1,217
|
1,109
|
854.2
|
994.7
|
1,284
|
EBITDA
1 |
484
|
206.5
|
46.58
|
-324.5
|
-354.1
|
196.2
|
EBIT
1 |
470.9
|
174.5
|
13.21
|
-362.8
|
-390.5
|
156.9
|
Operating Margin
|
29.09%
|
14.34%
|
1.19%
|
-42.48%
|
-39.26%
|
12.22%
|
Earnings before Tax (EBT)
1 |
452.2
|
158
|
17.51
|
-352.6
|
-420
|
100.4
|
Net income
1 |
374.1
|
130.1
|
32
|
-316.2
|
-398.7
|
90.08
|
Net margin
|
23.11%
|
10.69%
|
2.88%
|
-37.02%
|
-40.09%
|
7.02%
|
EPS
2 |
0.7571
|
0.2600
|
0.0700
|
-0.6400
|
-0.8100
|
0.1800
|
Free Cash Flow
1 |
-600.9
|
137.9
|
-1.029
|
-124.2
|
150.8
|
502
|
FCF margin
|
-37.12%
|
11.33%
|
-0.09%
|
-14.54%
|
15.16%
|
39.09%
|
FCF Conversion (EBITDA)
|
-
|
66.77%
|
-
|
-
|
-
|
255.9%
|
FCF Conversion (Net income)
|
-
|
106.02%
|
-
|
-
|
-
|
557.25%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/19
|
29/04/20
|
28/04/21
|
29/04/22
|
21/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
66.4
|
-
|
-
|
183
|
187
|
32.6
|
Net Cash position
1 |
-
|
64.9
|
57.9
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.1372
x
|
-
|
-
|
-0.5631
x
|
-0.5268
x
|
0.1662
x
|
Free Cash Flow
1 |
-601
|
138
|
-1.03
|
-124
|
151
|
502
|
ROE (net income / shareholders' equity)
|
18.2%
|
5.73%
|
1.2%
|
-14.4%
|
-21.6%
|
5.75%
|
ROA (Net income/ Total Assets)
|
10.5%
|
3.3%
|
0.23%
|
-6.57%
|
-8.38%
|
3.67%
|
Assets
1 |
3,557
|
3,944
|
14,217
|
4,811
|
4,755
|
2,457
|
Book Value Per Share
2 |
4.630
|
4.820
|
4.930
|
4.290
|
3.480
|
2.810
|
Cash Flow per Share
2 |
0.2500
|
0.4900
|
0.8000
|
0.3000
|
0.5000
|
0.4900
|
Capex
1 |
200
|
87.4
|
49.6
|
18.2
|
8.67
|
2.51
|
Capex / Sales
|
12.38%
|
7.18%
|
4.48%
|
2.13%
|
0.87%
|
0.2%
|
Announcement Date
|
25/03/19
|
29/04/20
|
28/04/21
|
29/04/22
|
21/04/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.82% | 1.74B | | +39.33% | 6.11B | | -18.38% | 4.35B | | -9.17% | 3.19B | | +3.98% | 3.15B | | -3.41% | 2.51B | | +48.74% | 1.98B | | -1.24% | 1.63B | | -8.96% | 1.6B | | +39.87% | 1.45B |
Alternative Medicine
|